Solid-phase synthesis of CD40L mimetics

被引：10

作者：

Bianco, A ^{[1
]}

Fournel, S ^{[1
]}

Wieckowski, S ^{[1
]}

Hoebeke, J ^{[1
]}

Guichard, G ^{[1
]}

机构：

[1] CNRS, Inst Biol Mol & Cellulaire, UPR 9021, F-67084 Strasbourg, France

来源：

ORGANIC & BIOMOLECULAR CHEMISTRY | 2006年 / 4卷 / 08期

关键词：

D O I：

10.1039/b601528j

中图分类号：

O62 [有机化学];

学科分类号：

070303 ; 081704 ;

摘要：

The C-3-symmetric molecule 1 has been previously shown to mimic CD40 ligand (CD40L) homotrimers and to display effector functions. This molecule consists of a cyclic hexapeptide core containing the repetition of the D-Ala-L-Lys motif. The side chains of the lysine residues have been modified by appending the CD40L-derived sequence (143)Lys-Gly-Tyr-Tyr(146) via a 6-aminohexanoic acid residue as a spacer. The present report describes a general solid-phase synthesis approach to 1 and related trimeric architectures. In addition, their CD40 binding properties as well as their effector functions have been evaluated.

引用

页码：1461 / 1463

页数：3

共 50 条

[21] Homocysteine modulates the CD40/CD40L system
Prontera, Cesaria
Martelli, Nicola
Evangelista, Virgilio
D'Urbano, Etrusca
Manarini, Stefano
Recchiuti, Antonio
Dragani, Alfredo
Passeri, Cecilia
Davi, Giovanni
Romano, Mario
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2007, 49 (22) : 2182 - 2190
[22] Immune properties of recombinant vaccinia virus encoding CD154 (CD40L) are determined by expression of virally encoded CD40L and the presence of CD40L protein in viral particles
Michal Bereta
Joanna Bereta
Jonas Park
Freddy Medina
Heesun Kwak
Howard L Kaufman
Cancer Gene Therapy, 2004, 11 : 808 - 818
[23] Microvascular thrombosis and CD40/CD40L signaling
Gavins, F. N. E.
Li, G.
Russell, J.
Perretti, M.
Granger, D. N.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2011, 9 (03) : 574 - 581
[24] Immune properties of recombinant vaccinia virus encoding CD154 (CD40L) are determined by expression of virally encoded CD40L and the presence of CD40L protein in viral particles
Bereta, M
Bereta, J
Park, J
Medina, F
Kwak, H
Kaufman, HL
CANCER GENE THERAPY, 2004, 11 (12) : 808 - 818
[25] Differences of soluble CD40L in sera and plasma: Implications on CD40L assay as a marker of thrombotic risk
Ahn, ER
Lander, G
Jy, W
Bidot, CJ
Jimenez, JJ
Horstman, LL
Ahn, YS
THROMBOSIS RESEARCH, 2004, 114 (02) : 143 - 148
[26] Herceptin and CD40L case examples
Clarke, Janet
Hutto, David
TOXICOLOGY, 2007, 240 (03) : 152 - 152
[27] Characterization and application of two novel monoclonal antibodies against CD40L: epitope and functional studies on cell membrane CD40L and studies on the origin of soluble serum CD40L
Fan, Y
Ge, Y
Zhu, H
Wang, Y
Yang, B
Zhuang, Y
Ma, H
Zhang, X
TISSUE ANTIGENS, 2004, 64 (03): : 257 - 263
[28] The role of soluble CD40L in immunosuppression
Schlom, Jeffrey
Jochems, Caroline
Gulley, James L.
Huang, Jianping
ONCOIMMUNOLOGY, 2013, 2 (01):
[29] Deregulation of CD 40/CD40L by HTLV-I tax
Janic, B
Ramos, JC
Harrington, WJ
Harhaj, E
AIDS RESEARCH AND HUMAN RETROVIRUSES, 2005, 21 (05) : 482 - 482
[30] Molecular identity of platelet CD40 ligand (CD40L)
Weber, AA
Hermann, A
Rauch, BH
Schrör, K
THROMBOSIS AND HAEMOSTASIS, 2001, 86 (02) : 718 - 718

← 1 2 3 4 5 →